Company Overview: ACAD

Upcoming Projects (ACAD)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ACAD)

Discussing Daybue in the commercial setting and ongoing trends in Rett Syndrome
Ticker: ACAD
Executed On: Feb 20, 2024 at 11:00 AM EST
A Second Look: Discussing Acadia Pharmaceuticals Daybue (trofinetide) in Rett Syndrome with a neurologist, in light of its recent FDA approval
Ticker: ACAD
Executed On: Mar 29, 2023 at 02:30 PM EDT
Discussing Acadia Pharmaceuticals Daybue (trofinetide) in Rett Syndrome with a neurologist, in light of its recent FDA approval
Ticker: ACAD
Executed On: Mar 21, 2023 at 11:00 AM EDT

Expired Projects (ACAD)

Analyzing Acadia Pharma’s (ACAD) Trofinetide in Rett Syndrome following top-line results from the Pivotal Phase 3 Lavender Trial
Ticker: ACAD
Execute By: Feb 17, 2022
Should investors be encouraged by the Nuplazid Alzheimer's Disease Psychosis data or questionable the decision to advance into Phase 3?
Ticker: ACAD
Execute By: Feb 10, 2017

Upcoming & Overdue Catalysts (ACAD)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ACAD)

Acadia Pharmaceuticals - primary endpoint not met in ACP-044 phase 2 trial for acute pain following bunionectomy surgery
Ticker: ACAD
Occurred on: Apr 18, 2022
Acadia Pharmaceuticals (ACAD) Announces Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Ticker: ACAD
Occurred on: Dec 06, 2021
Acadia's (ACAD) Pimavanserin in Alzheimer’s disease psychosis PDUFA date set for April 3, 2021, after FDA identified deficiencies that preclude discussion of labeling
Ticker: ACAD
Occurred on: Apr 05, 2021
Acadia's (ACAD) Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis Stopped Early for Positive Efficacy
Ticker: ACAD
Occurred on: Sep 09, 2019
FDA Analysis Issued for Acadia's (ACAD) NUPLAZID (pimavanserin) in Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
Ticker: ACAD
Occurred on: Sep 20, 2018
Top-line data for the Phase 2 CLARITY trial of Pimavanserin in Adjunctive Treatment, in Patients With Major Depressive Disorder due 2H 2018
Ticker: ACAD
Occurred on: Feb 27, 2018
Acadia (ACAD) Expects Top-Line Phase 2 Data Evaluating NUPLAZID in Alzheimer's Disease Psychosis in Q4 2016
Ticker: ACAD
Occurred on: Dec 20, 2016
Acadia (ACAD) Initiates Phase 2 ADVANCE Study Analyzing Nuplazid in Patients with Negative Symptoms of Schizophrenia
Ticker: ACAD
Occurred on: Nov 15, 2016
Acadia (ACAD) Commences Phase 3 Trial Evaluating Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
Ticker: ACAD
Occurred on: Nov 03, 2016
Acadia (ACAD) Announces Initiation of Phase 2 Study Evaluating Pimavanserin in Alzheimer's Disease Agitation
Ticker: ACAD
Occurred on: Oct 31, 2016
Update on the U.K.’S Competition and Markets Authority’s Review of Acadia Healthcare’s Acquisition of Priory Group
Ticker: ACAD
Occurred on: Jul 14, 2016
FDA Approves ACADIA Pharmaceuticals’ NUPLAZID (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
Ticker: ACAD
Occurred on: Apr 29, 2016
PDUFA action date for completion of FDA review of the NUPLAZID NDA set for May 1, 2016
Ticker: ACAD
Occurred on: Apr 29, 2016
PDUFA date May 1 2016 of NUPLAZID (Pimavanserin) for Parkinson's disease psychosis (PDP) - under priority review
Ticker: ACAD
Occurred on: Apr 29, 2016
Ad Comm meeting Scheduled for March 29, 2016 to Review NUPLAZID (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
Ticker: ACAD
Occurred on: Mar 29, 2016
ACADIA Pharma initiates $300M equity offering (10,000,000 Shares)
Ticker: ACAD
Occurred on: Jan 05, 2016
Acadia Healthcare acquires Priory Group for $1.8 bn
Ticker: ACAD
Occurred on: Jan 04, 2016

Strategic Initiatives (ACAD)

Don’t see a strategic initiative related to the company you care about? Create your own!

ACAD Overview